Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, parallel controlled design, phase I trial of REC610 for healthy adult subjects aged 40 and above in China

Next Previous
Trial Profile

A randomized, double-blind, parallel controlled design, phase I trial of REC610 for healthy adult subjects aged 40 and above in China

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs REC 610 (Primary)
  • Indications Herpes zoster
  • Focus Adverse reactions; Pharmacodynamics

Most Recent Events

  • 23 Mar 2024 New trial record
  • 20 Mar 2024 According to a Jiangsu Recbio Technology media release, company has completed enrollment of all subjects in this trial. EC610 has obtained the Notice on Drug Clinical Trial Approval (notice number: 2023LP02151) issued by the NMPA in October 2023, which is authorized to carry out phase I and phase III clinical trials in China as a Category 3.3 biological product for preventive use.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top